On July 15th Melanoma Research has published online results of a retrospective study on oncolytic virotherapy effectiveness on the overall survival of melanoma patients after surgical excision of the tumour. It was found that stage IB-IIC melanoma patients who were treated with oncolytic virotherapy had an 4.39-6.57 fold lower mortality rate than those treated according to current guidelines by observation.

Adapted ECHO-7 virus immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.

Jumeirah Lake Towers
Swiss Tower, office 204
P.O. Box 309073, Dubai, UAE

+ 44 20 38 684 002 (UK, London)
+ 1 646 88 33 419 (USA, New York)
+ 371 67 229 599 (Latvia)

© 2020 International Virotherapy Center Limited. All Rights Reserved